Human Genome Sciences Seeks to Fend Off GSK
May 18, 2012, 01:00 AM
by
Michael Croft
New York Times | Human Genome Sciences is still rejecting a bid from GlaxoSmithKline to buy the biotech. Human Genome Sciences' board voted unanimously to reject the GSK offer and adopt a shareholders' rights plan, or poison pill.
May 18, 2012 | Human Genome Sciences is still rejecting a bid from GlaxoSmithKline to buy the biotech. Human Genome Sciences' board voted unanimously to reject the GSK offer and adopt a shareholders' rights plan, or poison pill, to fend off GSK's advances. The pharma has made an open offer of $13/share that expires June 7. New York Times